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CASE PRESENTATION
A 27-year-old Asian woman was admitted to the hospi-
tal for swelling of her legs over the previous 2 to 3 days. A
primigravida, she was 30 weeks pregnant. She had been
well and had no prior history of hypertension, diabetes,
or renal disease. She saw her physician every month and
had had no previous swelling. Her prior blood pressure
measurements and urinalyses had been normal. The ini-
tial serum creatinine when she was 6 weeks pregnant was
0.6 mg/dL. When she saw her obstetrician the morning
of admission, she felt otherwise well. The examination
was unremarkable except for a blood pressure of 160/
100 mm Hg, which was unchanged 30 minutes later,
and significant pretibial edema. Her reflexes were nor-
mal. Urinalysis demonstrated 3+ protein without blood,
sugar, leukocytes, or nitrate. Laboratory tests revealed
a serum creatinine of 0.9 mg/dL, uric acid of 5.0 mg/dL,
and normal coagulation studies and liver enzymes. A spot
urine protein-to-creatinine ratio was 1.8.
The patient was admitted to the hospital for bed rest.
Fetal ultrasound showed the fetus to be without defect;
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the estimated gestational age was 29 weeks. Serial blood
pressure measurements demonstrated a range of 150 to
180/95 to 105 mm Hg. The patient was given labetalol,
100 mg twice daily. Serial non-stress testing showed that
the fetus continued to do well, but the patient’s blood
pressure became difficult to control over the following
week. Her blood pressure climbed to 160/100 mm Hg de-
spite maximal doses of labetalol and alpha-methyldopa.
Her 24-hour urine protein content had increased to ap-
proximately 3 g, and the serum creatinine had risen to
1.1 mg/dL, with a creatinine clearance of 85 mL/min.
During her second week in the hospital, the patient was
treated with corticosteroids to accelerate fetal lung matu-
rity. She continued to be mildly hypertensive with mod-
erate edema and normoreflexia. A cesarean section was
undertaken at the end of the second week, when labo-
ratory studies demonstrated a mild increase in aspartate
aminotransferase (AST) and amino alanine transferase
(ALT) and her serum creatinine increased to 1.2 mg/dL.
A baby boy weighing 3 lbs, 2 oz was delivered and did
reasonably well. He required supplemental oxygenation
and was cared for in the neonatal intensive care unit. He
was discharged 4 weeks later without significant compli-
cation. The patient’s swelling abated quickly after deliv-
ery. Her blood pressure was normal. Within one week, the
serum creatinine was 0.8 mg/dL, and the urine protein-
to-creatinine ratio was 0.15. Six months later, she was
seen by her primary medical doctor. Her examination
was normal: the blood pressure was 115/75 mm Hg, her
serum creatinine was 0.8 mg/dL, creatinine clearance was
104 mL/min, and urinary protein excretion was 38 mg/day.
DISCUSSION
DR. RICHARD LAFAYETTE (Associate Professor of
Medicine, Stanford University Medical Center, Clinical
Chief, Division of Nephrology, Stanford, California):
Preeclampsia remains a major cause of maternal and
fetal morbidity and mortality in the United States and
the world. Approximately 1 in 20 pregnancies is compli-
cated by this disorder. Although there are many systemic
manifestations of preeclampsia, its clinical hallmarks
of hypertension, edema, and proteinuria reflect signifi-
cant kidney dysfunction. This review aims to detail the
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pathophysiologic changes of the kidney that distinguish
preeclampsia from normal pregnancy.
Definition
Preeclampsia has been defined as the onset of hyper-
tension (blood pressure ≥140/90 mm Hg) with protein-
uria (urine dipstick ≥2+ or urine protein >300 mg/day)
and edema. This clinical triad, occurring in the second
half of pregnancy, fulfills the criteria of the American
Congress of Obstetrics [1, 2]. It must be distinguished
from worsening renal disease during pregnancy (usually
by history) and from pregnancy-induced hypertension
without proteinuria, another common entity. In women
with underlying hypertension, preeclampsia generally is
identified by elevation of prevailing blood pressure lev-
els and the development of proteinuria. Women are at
increased risk when a first-degree female blood relative
has had preeclampsia; if they have high blood pressure, di-
abetes, kidney disease, or migraine; they are over 35 years
old; or they are multigravid [3, 4]. The major clinical risk
is progression to eclampsia, an acute seizure disorder,
but the disease also can lead to multiorgan failure with
catastrophic consequences. Within the kidney, the pre-
dominant change occurs in glomerular endothelial cells.
There may also be hemodynamic changes. To best under-
stand the latter, let’s review the normal renal physiology
in pregnancy.
The kidney in normal pregnancy
Pregnancy produces marked physiologic changes
throughout the body. Systemic hemodynamics are al-
tered, with dramatic increases in total circulating blood
volume, increased cardiac output, and reduced systemic
resistance. The net result is a high-output state with a
mildly reduced blood pressure [5].
Studies of human pregnancy that have utilized inulin,
the most reliable filtration marker, have demonstrated
that glomerular filtration rate (GFR) increases progres-
sively during the first half of pregnancy [6–10]. It then
reaches a peak level that exceeds nongravid GFR by 40%
to 60%, after which it remains constant until the end of
pregnancy [9–11]. This level of hyperfiltration extends
into the first postpartum day, and hyperfiltration of lesser
magnitude (± 20%) persists into the second postpartum
week [11, 12].
The GFR can be equated with the product of Kf and
the net pressure for ultrafiltration
GFR = (P−GC) × Kf
where P is the transcapillary hydraulic pressure differ-
ence, GC is the mean glomerular intracapillary oncotic
pressure, and Kf is the glomerular ultrafiltration coeffi-
cient, the product of hydraulic permeability (k) and filtra-
tion surface area (S) [13]. Determinations of renal plasma
flow (RPF), filtration fraction, and arterial oncotic pres-
sure (p A) during peak gestational hyperfiltration in late
pregnancy and on postpartum day 1 reveal that GC is
depressed by between 3.3 and 6.7 mm Hg [10]. In the
event that neither P nor Kf is altered by gestation, an
equivalent increase in the net filtration pressure for ultra-
filtration could account exclusively for the increased level
of glomerular filtration. However, other workers have in-
terpreted an alteration in the transglomerular sieving of
macromolecules as indicating that, in addition to depres-
sion of p GC, an approximate 15% increase in Kf is re-
quired to account for the 38% increase in GFR observed
by them in late pregnancy [6]. That this might be so is con-
sistent with micropuncture determinations of Kf in the
healthy pregnant rat [14]. Because the rats in this study
were at filtration pressure equilibrium, unique values of
Kf could not be determined, and conclusions regarding Kf
could not be drawn. Evidence that Kf elevation might be
implicated is provided from a separate, more recent study
in which filtration dynamics were compared in gravid ver-
sus nongravid rats with a remnant kidney [15]. Because
this experimental model is associated with filtration dise-
quilibrium, unique values for Kf could be calculated. The
authors reported a greater than 2-fold increase in this
measure, which accounted for the hyperfiltration in the
pregnant animals, and they suggested that Kf elevation
could well be implicated in gestational hyperfiltration.
One mechanism by which Kf might be increased in
pregnancy is through glomerular hypertrophy. Glomeru-
lar volume has not been determined during normal preg-
nancy. However, given the demonstration of increased
kidney size and volume during pregnancy [16, 17], it is
possible that glomeruli hypertrophy and that this change
is accompanied by an increase in filtration surface area
and hence, Kf. Our own study supports this finding: we
noted a glomerular volume of 5.23 ± 2.16 lm/lm3 × 106
in women with preeclampsia, a value 2.3-fold larger than
the corresponding value in healthy, nongravid female
controls [18]. Our preeclamptic patients also exhibited
considerable endocapillary cell proliferation and hyper-
plasia, more markedly in glomerular endothelial than in
mesangial cells. We surmise that the expansion of the en-
docapillary cell compartment contributed significantly to
the glomerular enlargement. Any glomerular hypertro-
phy attributable to pregnancy alone is thus likely to be
of substantially smaller magnitude, such as less than by a
factor of 2.0.
That Kf enhancement by a factor of ± 50% could be
associated with pregnancy is also suggested by our re-
cent study of healthy mothers on postpartum day 10 [11].
We found that glomerular capillary oncotic pressure had
been restored to normal at this time, consequent upon
reversal of the pregnancy-mediated hemodilution. Us-
ing a mathematical model of glomerular filtration, we
computed that an increase of Kf by 50% could account
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exclusively for the maintenance of the increased GFR by
20% in postpartum week 2 [11].
It seems reasonable to conclude that elevation of ul-
trafiltration pressure due to a low glomerular capillary
oncotic pressure is the predominant cause of gestational
hyperfiltration. An additional contribution by Kf owing
to gestational-induced hypertrophy of glomeruli seems
likely, but this remains to be proven. At present, there is
no way to estimate P in the human kidney. If anything,
however, one would speculate that relative hypotension
during pregnancy could be transmitted into the glomeru-
lar capillary, thereby lowering P, and that this change
would lower, not elevate, the GFR.
Preeclampsia
Preeclampsia is characterized by gestational hyperten-
sion, a phenomenon that has been attributed to an excess
of vasoconstrictor over vasodilator influences in the sys-
temic circulation [19–21]. A parallel imbalance in the re-
nal circulation would be expected to lower the glomerular
perfusion rate. Another characteristic of preeclampsia is
abnormal glomerular morphology [22, 23], which could
lower the intrinsic ultrafiltration capacity of glomeru-
lar capillaries. Limited glomerular ultrafiltration capac-
ity on its own, or more particularly, in combination with
glomerular underperfusion, results in depression of the
GFR. Similar to the observations of others during late
pregnancy, the GFR in our gravid control subjects was el-
evated above normal non-gravid levels by approximately
50%, averaging 149 ± 34 mL/min/1.73m2 [8, 12, 18]. When
compared to this high value, the corresponding GFR in
patients with preeclampsia was significantly depressed,
averaging only 91 ± 25 mL/min/1.73m2. Of note, the
corresponding levels of serum creatinine in the control
and preeclampsia groups were 0.60 ± 0.10 and 0.83 ±
0.22 mg/dL, respectively. Because of the hyperbolic re-
lationship between this quantity and GFR, the highest
serum creatinine level in the preeclampsia group was
only 1.2 mg/dL, despite simultaneous depression of cor-
responding GFR to 44 mL/min/1.73m2 [18].
Unlike the GFR, renal plasma flow in gravid controls
was not elevated above normal non-gravid levels in our
study, averaging 624 ± 108 mL/min/1.73m2 [18]. The cor-
responding renal plasma flow in the preeclampsia group
was similar, averaging 648 ± 257 mL/min/1.73m2 (P =
NS). The selective decline of GFR resulted in marked
depression of the filtration fraction. This latter finding in-
dicates that determinants of GFR other than renal plasma
flow must have been altered to explain the observed level
of hypofiltration.
A consistently reported finding of hypoalbuminemia in
pregnancy has been attributed to a combination of hyper-
volemia (hemodilution) and altered protein metabolism
[24–26]. We found serum albumin concentration to be
markedly depressed in women with normal pregnancy
and with preeclampsia, slightly more so in preeclamp-
sia, 1.87 ± 0.20 versus 1.95 ± 0.22 g/dL, respectively [18].
In fact, measured oncotic pressure is low in preeclamp-
sia, resulting in a depression in p GC. This phenomenon
is likely related to the significant proteinuria that de-
fines the disease. However, as p GC is the force opposing
the formation of filtrate, the trend toward depression of
this quantity should have increased ultrafiltration pres-
sure and hence, increased GFR [13]. It follows that de-
pression of either the glomerular transcapillary hydraulic
pressure difference and/or the glomerular ultrafiltration
coefficient (Kf) must be invoked to explain the hypofil-
tration observed in preeclampsia.
It seems doubtful that P depression generally could
make a major contribution to the observed hypofiltration
in preeclampsia, however. One reason for doubt is that
mean arterial pressure in preeclampisa is usually quite
elevated. Despite the mild trend to higher renovascu-
lar resistance in preeclampsia, it is difficult to imagine a
selective increase in preglomerular segmental resistance
of sufficient magnitude to prevent some fraction of the
excess in arterial pressure from being transmitted into
glomerular capillaries.
Our own morphometric analysis of glomeruli suggests
that an important and perhaps predominant reason for
the hypofiltration in preeclampsia is impaired hydraulic
permeability of glomerular capillary walls, owing mainly
to reductions in endothelial cell fenestral density and size,
and to the accumulation beneath the endothelial mono-
layer of fibrinoid deposits.
Examination of the preeclamptic kidney by light mi-
croscopy reveals the typical prominence of endocapillary
(mesangial and endothelial) cells. This pattern has been
well described by others for more than 80 years but had
not previously been directly linked to renal dysfunction
[22, 27]. Our study [18] disclosed conspicuous endothelial
cellularity in most cases, evidenced by up to 3 endothelial
cell nuclei in some capillary lumens. Definite mesangial
hypercellularity was difficult to discern. We also found a
prominent infiltration of macrophages and a lesser num-
ber of lymphocytes and polymorphonuclear leukocytes
within capillary lumens in 4 of the 11 patients. The hyper-
trophy of endothelial cells alone, or in combination with
leukocyte infiltrates, resulted in obvious loss of capillary
patency in all cases. Foamy macrophages were found in
2 of the patients. We also noted variable thickening of
glomerular capillary walls, which was related to mesan-
gial interposition in all cases, and prominent subendothe-
lial hyaline deposits in one. An additional finding was
the presence of early focal segmental glomerular scle-
rosis in 4 of 7 of the women, affecting 19 ± 11% of
glomeruli, on average. Transmission electron microscopy
confirmed the finding of endothelial cell hyperplasia, and
revealed exudation of foamy macrophages, lymphocytes,
Nephrology Forum: The kidney in preeclampsia 1197
Fig. 1. Transmission electron microscopy of a representative glomeru-
lar capillary enumerating pathologic changes associated with
preeclampsia.
and polymorphonuclear leukocytes within the capillary
lumina and mesangium. In addition, capillary wall ab-
normalities were apparent (Figs. 1 and 2). These included
hypertrophied endothelial cells, swollen segments of en-
dothelial cytoplasmic rim in which fenestrae were not dis-
cernible, subendothelial fibrinoid and granular deposits,
and interposition of mesangial cells.
Glomerular volume in preeclampsia was significantly
larger than in controls, 5.23 ± 2.16 versus 3.29 ±
1.19 lm/lm3 × 106, respectively (P < 0.05) [18]. We
defined “effective” filtration surface as that part of the
peripheral GBM that was apposed to the fenestrated en-
dothelial cytoplasmic rim. The remaining part of the pe-
ripheral GBM that was apposed to endothelial cell bodies
or interposed mesangial cells (numbers 1 and 4, respec-
tively, of Fig. 2) was excluded on the grounds that tran-
scellular filtration is negligible. This latter component,
which comprises “ineffective” filtration surface density,
was increased by a factor of 3 in preeclampsia versus
controls (0.024 ± 0.001 versus 0.008 ± 0.001, lm2/lm3,
P= 0.001) mostly as a consequence of interposed mesan-
gial cells. As a result, effective filtration surface density
(Sv) was reduced in preeclampsia versus controls, aver-
aging 0.055 ± 0.002 versus 0.100 ± 0.013, lm2/lm3 (P <
0.001). However, a trend to larger glomerular volume in
preeclampsia offset the reduction in Sv. As a result, ac-
tual filtration surface area in preeclampsia was reduced
below control by only 10%.
We did find, however, extensive dense deposits of fib-
rinoid material in a subendothelial location [18]. These
deposits produced a proportionately greater thickening
of the entire filtration pathway, from fenestral interface
to slit diaphragm in preeclampsia. Scanning and trans-
mission electroscopy demonstrated that fenestral density
was lower in women with preeclampsia than in controls.
A smaller area-to-perimeter ratio also attested to a re-
duction in endothelial fenestral size in preeclampsia. To-
gether, reduced fenestral density and size in preeclampsia
resulted in a smaller fraction of GBM occupied by fenes-
trae than in controls. This phenomenon is clearly visible
by inspection of the digitized tracings that are taken from
a control (Fig. 3, left) and a representative subject with
preeclampsia (Fig. 3, right).
We calculated that overall k in preeclampsia was re-
duced below control by 30%. In contrast, effective fil-
tration surface area (S) was only slightly reduced. From
the product of S and k, we compute that SNKf in con-
trols averaged 6.78 nL/(min×mm Hg).The correspond-
ing value in preeclampsia was substantially lower, 4.26
to 4.67 nL/(min×mm Hg). We found a 37% reduction in
estimated SNKf; this change is remarkably similar to the
corresponding reduction of 39% in observed GFR in this
disorder. The above rationale suggests that Kf depres-
sion is indeed the predominant cause of hypofiltration in
preeclampsia, and that it is unnecessary to invoke a sub-
stantial role for simultaneous depression of P or RPF
in these patients.
Pathogenesis of the renal injury
Unraveling the complex injury of preeclampsia has
been an elusive task [28]. The disorder appears to have
immunologic, genetic, and biochemical components that
have made the identification of a common, mediating
pathogenetic factor difficult. To date, no single gene mu-
tation has been strongly associated with the disorder de-
spite a fairly strong familial tendency [29]. Because of the
prominent findings of endothelial injury with vasocon-
striction and clotting activation, a number of hormonal,
neurogenic, and other circulating factors have been im-
plicated in this process (Table 1).
Unfortunately, no specific, successful therapy has been
discovered for preeclampsia. To the contrary, allegedly
promising therapies, such as aspirin and supplemental
calcium, have proved of little or no value [30, 31].
Earlier research focused on prostaglandins, and re-
searchers sought an imbalance leading to a deficiency of
vasodilatory, antithrombotic prostanoids relative to vaso-
constrictor and prothrombotic prostanoids [32]. While
some data favor a possible imbalance in prostanoid tone,
treatment with aspirin has proved of questionable value,
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Fig. 2. Ultrastructural changes in preeclampsia seen in Figure 1. 1, endothelial cell body; 2, swollen, non-fenestrated endothelium; 3, subendothelial
fibrinoid deposition; 4, mesangial cell interposition.
Fig. 3. Scanning electron microscopy and digitized tracings of fenestrae in control (1A and 1B) and in subject with preeclampsia (2A and 2B).
and other potentially causative factors were subsequently
evaluated [32]. Recently, a major effort was made to link
disorders in the nitric oxide (NO) system with the clini-
cal features of preeclampsia [33]. Indeed, up-regulation
of the NO system has been reported in normal pregnancy
and is believed to contribute to the hyperperfusion and
hyperfiltration, as well as to the systemic hemodynamic
changes of normal pregnancy [33]. Preliminary evidence
suggested down-regulation of nitric oxide synthase in the
placenta and in blood and decreased activity of its second
messenger, cyclic GMP [34]. The findings are conflicting,
however, and failure of L-arginine to up-regulate the NO
system or influence glomerular injury in a recent trial
suggests that the NO system might not have a major role
(personal data, presented at the 36th annual meeting of
the American Society of Nephrology, 2005).
Efforts at understanding preeclampsia are under-
pinned by the knowledge that abnormalities in the
placenta are universal in preeclampsia. Placental insuffi-
ciency, defined by inadequate development of uterine spi-
ral arteries into high-capacity vessels to feed the placenta,
is present in patients with preeclampsia [35]. Delivery of
the fetus rapidly resolves the clinical syndrome. Thus ef-
forts to understand placental insufficiency might unravel
the pathophysiology of preeclampsia. Notable are studies
by Fisher et al demonstrating basic defects in trophoblast
function [36, 37]. The normal process of placental devel-
opment requires invasion of trophoblasts into the uterine
Table 1. Pathogenetic processes implicated in preeclampsia
Increased activity of the sympathetic nervous system
Increased responsiveness to angiotensin II
Hypocalciuria
Defects in atrial natriuretic peptide (ANP)
Increased angiotensin II agonistic autoantibodies
Failure to increase placental-derived vascular growth factors (PlGF)
due to soluble inhibitors
Increased endothelin
Decreased activity of the nitric oxide system
Platelet activation through changes in clotting factors and
platelet-related molecules, such as antithrombin III, vWF,
platelet-activating factor
Increased ratio of thromboxane-to-prostacyclin
Defects in adrenocorticoid regulation
Increases in inflammatory cytokines
Placental vascular insufficiency
Insufficient differentiation of trophoblasts to endothelial cells
Other circulating toxins, including uric acid, parathyroid hormone,
and “trophotoxins”
Reduced levels of relaxin
vasculature, with loss of differentiation from an epithe-
lial to an endothelial phenotype. This differentiation,
which appears to be significantly defective in women with
preeclampsia, can lead to inadequate oxygen delivery to
the placenta and the release of mediators of endothelial
injury. In turn, the hypoxic, injured placenta may cause
many downstream events, such as the release of inflam-
matory cytokines or the development of angiotensin II
receptor autoantibodies, which can propagate endothe-
lial injury [38, 39]. This sequence of events also might be
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associated with the recent finding that normal pregnancy
is associated with high levels of a placental-derived vascu-
lar growth factor (PlGF), similar to vascular endothelial
growth factor, VEGF [40]. It appears that many women
with preeclampsia, although not all, have high levels of
a circulating inhibitor of this hormone (a soluble recep-
tor, sFlt) [41]. The resultant deficiency of vascular growth
factor activity might contribute to the hypertension, pro-
teinuria, and renal injury that defines preeclampsia.
Still, great uncertainty remains. What is the primary
change in preeclampsia? Which of the described abnor-
malities are downstream changes caused by the initial
injury? Ongoing and future trials might better determine
the pathogenesis of this disorder and lead to specific ther-
apy. Currently, supportive care with control of blood pres-
sure and prophylaxis against seizures is the only therapy
shy of delivery of the child, as in this case.
QUESTIONS AND ANSWERS
DR. JOHN T. HARRINGTON (Dean Emeritus, Tufts-New
England Medical Center, Boston, Massachusetts): Are the
lesions elsewhere in the body in preeclampsia compara-
ble to those in the kidney?
DR. LAFAYETTE: Data are limited, but there are
some necropsy data from patients who have died from
preeclampsia and its complications [42]. We originally hy-
pothesized that the predominant pathology in preeclamp-
sia was thrombotic microangiopathy. It appears that
diffuse endothelial dysfunction causes platelet aggrega-
tion that leads to ischemic and necrotic changes. Broad
evidence for this in these autopsy series demonstrates vas-
cular injury in multiple organs, including the brain, liver,
and lungs. Clearly, it is not solely the kidney that suffers
from this systemic disease. However, renal damage might
be due to the intimacy of the glomerular circulation with
renal function, thus rendering renal issues more easily
seen.
DR. HARRINGTON: Is the higher capillary pressure in
the glomerulus, as compared to non-renal capillaries, the
cause of the more severe involvement of the kidney?
DR. LAFAYETTE: I don’t know whether the kidney
is more susceptible than other organs to the endothe-
lial injury of preeclampsia, but it certainly is the classic
organ involvement described. Whether or not it is the
uniquely high capillary pressure in the glomerulus that
leads to organ specificity is of interest, but I have no
data supporting that notion. We do know that our car-
diology colleagues blame turbulent flow and shear stress
for some of the endothelial injury that occurs in coro-
nary and carotid vessels in patients with atherosclerosis.
Although it’s an attractive hypothesis, it would require
further investigation.
DR. HARRINGTON: What is the cause of the in-
creased fluid intake and polyuria in pregnant women?
The fact that these women are hyponatremic and vol-
ume expanded would argue that thirst must have another
stimulus.
DR. LAFAYETTE: I don’t know. Basically, the theory is
that the volume expansion and hyperfiltration of preg-
nancy produce active glomerulotubular balance and lead
to a diuresis. However, because of the physiologic ad-
justment in neuronal and hormonal tone in pregnancy,
the expanded volume is maintained and gradually in-
creased throughout pregnancy by net sodium retention.
The mechanism of the increased thirst has not been well
studied. It is clear that angiotensin II levels, a major stim-
ulus for thirst, are increased in pregnancy, but there is re-
sistance to their pressor effect [43], so it is unclear whether
angiotension II effectively stimulates thirst. Also, antid-
iuretic hormone (ADH) is reset in pregnancy, allowing
for hyponatremia, and also becoming more responsive to
any reduction in volume.
DR. JANE TAN (Assistant Professor of Medicine, Stan-
ford University): What is remarkable to me about
preeclampsia is its rapid reversibility, a characteristic
rarely seen in other glomerular diseases. For example,
after delivery, the patient’s blood pressure, GFR, and uri-
nary protein pretty much returned to baseline conditions.
The representative renal biopsy in preeclampsia that you
showed earlier looked horrendous (Fig. 1), with its se-
vere swollen basement membrane and mesangial inter-
position. In most other glomerular diseases, that degree
of histologic damage would result in significant residual
impairment even after treatment. Are there any data on
renal histology following the resolution of preeclampsia?
In other words, is there complete ultrastructural resolu-
tion? And if there is, what are the leading theories on how
this great repair occurs?
DR. LAFAYETTE: I would point out that we are obvi-
ously selecting some best examples of the morphologic
changes. Remember these are women with, on average,
very mild renal dysfunction, and the renal injury is not
as severe as that which we see in our typical patient with
hemolytic-uremic syndrome or thrombotic thrombocy-
topenic purpura (TTP). Even patients with severe acute
renal failure from thrombotic microangiopathy some-
times recover. There is something about those kinds of
injuries, which include swelling, edema, and inflamma-
tion that certainly should be reversible. How the kidney
clears the deposition of the fibrinous material and early
scar formation is harder to know, but more and more pro-
teolytic mechanisms in the kidney have been described
[44]. As the mesangial cells can invade the peripheral
capillary loop under certain influences, they should be
able to retract again. As an example, in mesangial pro-
liferative diseases, in some patients, the proliferation re-
solves during recovery. Essentially, glomerular diseases
that don’t reach the level of scarring, and perhaps even
some of those that are resolved early, probably can be
fully reversed. Obviously, underlying the reversibility is
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the idea that whatever caused the endothelial injury dis-
appears with delivery of the baby and the placenta, and
this change allows repair mechanisms to occur. Kincaid-
Smith et al have done serial biopsy studies of preeclamp-
tic patients in recovery and have readily demonstrated
that these processes reverse themselves [23]. In order,
first the swelling goes away, then interposition goes away,
and it takes a little bit longer, not unexpectedly, for the
fibrinous material to disappear. It can take months for
that to fully disappear, despite the fact that the GFR im-
proves and proteinuria resolves rapidly. One interesting
point is that in Japanese biopsy studies [45] and even in
our studies [18], many preeclamptic women have scle-
rotic injuries that look like focal segmental sclerosis. Even
those patients tend to get completely better clinically and
have normal GFR and protein excretion. No registry has
documented what happens to a preeclamptic patient 20
to 30 years later, but most of these women successfully
maintain excellent renal function, and even though there
is an increased risk of them developing high blood pres-
sure, it is not clear whether that is because they lose
some nephrons during this illness or because hereditary
or other factors predispose them to hypertension in the
first place.
DR. JEFFREY PETERSEN (Professor of Medicine, Stan-
ford University): Are there any known effects of the cir-
culating inhibitory factors that you are describing in the
studies out of the Beth Israel reported by Maynard et al
[40, 41]?
DR. LAFAYETTE: Other than their direct effect on re-
ducing the activity of VEGF and PlGF by binding them, I
haven’t seen anything written about them. What I would
point out from these studies is that they’ve utilized in vitro
techniques to show that these factors can inhibit vascular
growth. Further, in vivo they can create an animal model
that looks a lot like preeclampsia by infusing these solu-
ble inhibitors. The animals become hypertensive and de-
velop proteinuria, and they develop a glomerular pattern
that looks similar to the human endotheliosis. Taken to-
gether with the demonstration of increased levels of these
angiogenic inhibitors in preeclamptic women, it lends a
lot of credence to the theory that this contributes to the
development and severity of preeclampsia. In humans, it
is also interesting that VEGF inhibitors in clinical prac-
tice for treatment of cancer patients have been associated
with the development of hypertension and proteinuria.
To date, there are no biopsy studies of these patients, but
this association lends further strength to the hypothesis
that there is a chronic dependence of the glomerulus on
endothelial growth factors. If, indeed, endothelial growth
factors are inhibited in preeclampsia, this inhibition might
contribute to the renal injury.
DR. TIMOTHY MEYER (Professor of Medicine,
Stanford University): My question is related to
Dr. Harrington’s. It is thought that VEGF is produced
in the podocytes and causes the endothelial cells of the
glomerulus to be fenestrated. The inhibitor therefore
might remove the tonic VEGF effect, which is necessary
to preserve normal glomerular endothelial structure. Do
you see endothelial pathology in the kidney outside the
glomerulus when you perform biopsies?
DR. LAFAYETTE: Generally, morphologic changes out-
side the glomerulus have not been investigated. I am sure
you are aware that work suggested that VEGF has impor-
tant effects in the peritubular capillaries allowing for fluid
and electrolyte flux in the distal tubule [46]. As we had
focused our attention on glomerular dynamics, we did
not carefully examine the interstitium. However, there
doesn’t tend to be upstream arteriolar damage, and we
haven’t seen obvious evidence in peritubular capillaries
of congestion or of injury. There isn’t a lot of tubular dam-
age and so, in terms of other non-glomerular endothelium
within the kidney, we did not notice anything obvious in
terms of fibrin thrombi, even in the larger vessels. But we
did not look systematically.
DR. MAURICE DRUZIN (Professor of Obstetrics, Stan-
ford University): The renal lesion is a unique component
of this disease. Patients with chronic renal disease of any
type, whether it is vasculitis, chronic hypertension, or any
condition that has renal involvement, have an almost uni-
versal incidence of developing preeclampsia or superim-
posed preeclampsia. There is definitely something special
about the kidney that seems to be the focus of endothelial
cell damage.
DR. LAFAYETTE: I think there are two parts to that.
The injured kidney is vulnerable in pregnancy because
of the physiologic changes that occur, and probably be-
cause of unsuccessful adaptation to hyperfiltration. It is
often very difficult to know whether the underlying kid-
ney disease occurs because of hemodynamic changes or
other hormonal changes, or whether the patient is really
developing preeclampsia. If you have a patient with an
elevated baseline serum creatinine level, proteinuria, and
hypertension, and who becomes more hypertensive and
proteinuric during her pregnancy, is that preeclampsia, or
is it that the renal disease has worsened? Nephrologists
would very infrequently biopsy a patient like this, because
we don’t have any special therapy in either case. So, it is
interesting to know whether renal insufficiency or renal
disease itself would amplify the response to pregnancy
that causes preeclampsia, or whether we’re just seeing
another consequence of pregnancy in an abnormal, un-
healthy kidney.
DR. DRUZIN: There is also an increased risk among
women with very mild kidney disease or even simple di-
abetes or hypertension.
DR. LAFAYETTE: Yes, and one would wonder whether
this is because those underlying problems have already
initiated a very early pattern of endothelial dysfunction
that predisposes these women to preeclampsia.
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DR. HARRINGTON: You mentioned the genetics of
preeclampsia and some familial risks. Do we know any-
thing about specific genes or gene clusters using microar-
rays that we have these days to investigate that?
DR. LAFAYETTE: There has been a long-term interest
in the genetics of preeclampsia, because there is familial
clustering in preeclampsia. If you have a first-degree rel-
ative who has had preeclampsia, your risk increases sub-
stantially. Investigators have looked for genetic patterns
in these affected families, searching for genes that under-
lie hormonal abnormalities, hypertension abnormalities,
renin-angiotensin system changes, as well as clotting sys-
tem abnormalities. But there is no support for a mono-
genic abnormality underlying the disease. Some links to
HLA types have been noted, but these links have not
proven to be predictive of disease. So investigators moved
to a genomic approach to see what genes are differen-
tially expressed in preeclampsia. In fact, that is how they
found the defect in the regulation of placental growth
factor. Further data from Boston’s Beth Israel Hospi-
tal have followed up from clues found from gene chip
technology and genomics [47]. Researchers are looking
at other factors, such as genes that regulate insulin resis-
tance, because there has been a separate clinical correlate
that women with preeclampsia seem to be more prone to
insulin resistance [48]. This, of course, is another state
of endothelial dysfunction, and some genetic correlates
have been noted, at least in terms of RNA and protein
production, that reflect insulin resistance. But in terms of
trying to lay the burden for this disease on a single gene
defect, investigators have not been successful.
DR. TAN: What about the flip side? You’ve elaborated
on the genetic variances in pregnant women that could
render some more susceptible to preeclampsia. Is there
any evidence of increased susceptibility to preeclampsia
with specific fetus and mother pairs? In other words, are
there examples of a change in the risk of preeclampsia
after a woman changes partners?
DR. LAFAYETTE: Among the many theories was a very
strong belief that an immune response to the placental-
fetal unit leads to a cytokine-fueled inflammatory reac-
tion that then produces endothelial damage. The main
evidence for this is that there is an inflammatory mi-
lieu in preeclampsia with elevated levels of many cy-
tokines. Furthermore, epidemiologic evidence indicates
that women who have never had preeclampsia and then
change partners have a similar risk of preeclampsia as
primigravidas. Also, some women who have recurrent
preeclampsia and change partners have normal preg-
nancies [49]. This suggested that immune determinants
passed to the fetus from the father were involved in the
pathogenesis. Furthermore, epidemiologic evidence in-
dicates that women who change partners and who have
never had preeclampsia might get preeclampsia. Some
women who had preeclampsia and changed partners
didn’t get preeclampsia again, and that was the level of
evidence. We do not have much data about the role of
ABO or HLA incompatibility and the risk for pregnancy
complications. Recently, a large, long-term epidemiologic
trial examined the effect of changing partners on the in-
cidence of preeclampsia, and suggested that other factors
involved in subsequent pregnancies determined the out-
come rather than the changing of the male partner [50].
Thus, this immunologic concept is more in doubt. Still,
many laboratories are looking at cytokines in preeclamp-
sia, and looking at cytokine inhibitory strategies. Most
of the data suggest that a lot of cytokine and hormonal
changes are very much downstream events, and while you
might have some ability to change some of the clinical fea-
tures of the disease by manipulating the response, you are
unlikely to prevent it. We desperately need to have a bet-
ter understanding of the upstream events. Even for the
disturbances of angiogenesis, it is unclear how much of
the changes are cause or consequence. We await clinical
trials of endothelial growth factors to assess their impact
on this disorder.
DR. IVONA BERSKA (Community pediatrician): Does
the preeclampsia increase in women who have subse-
quent pregnancies?
DR. LAFAYETTE: I will ask Dr. Druzin to help me
with this. My understanding has been that once you
have preeclampsia, your risk of disease in subsequent
pregnancies is very much increased. The relative risk in-
creases substantially, I believe 4- to 5-fold. The severity
of preeclampsia, however, seems to be consistent with
what it was before, and it doesn’t tend to accelerate to
the point that you can predict increasing severity in sub-
sequent pregnancies. Thus, it does not appear to be an
issue of “sensitization” to pregnancy with conditioning
from prior pregnancies. Instead, if you have numerous
risk factors, such as hypertension, diabetes, renal disease,
then your risk for severity does increase.
DR. DRUZIN: On the question of some type of genetic
or immunologic basis, we used to think that if a woman has
preeclampsia during her first pregnancy, she is protected
subsequently. In fact, mild preeclampsia, which is late-
onset disease, is probably a different disease than what
we are looking at, which is severe and early preeclampsia.
The presentation of mild preeclampsia is very different
compared to the severe form of the disease. There is no
growth restriction of the fetus, there is clearly not a lot
of placental disease, and all you see is some hyperten-
sion and proteinuria. The earlier and more severe disease,
which is usually defined as occurring at gestational ages of
less than 34 weeks, has a distinctly different presentation
compared to mild preeclampsia. In patients with previ-
ous mild preeclampsia, the recurrence risk is 2% to 5%
with the same partner. If the patient has a new partner,
it used to be thought that the risk reverts to that of a first
pregnancy, which is doubled at 6% to 8%. The Norwegian
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epidemiologic study did not find this to be true after fol-
lowing patients for a prolonged period [50]. With severe
preeclampsia at 34 weeks or less, HELLP syndrome, or
eclampsia, the recurrence risk is between 20% and 25%
of developing repetitive severe disease, and about 40%
to 50% of developing some type of hypertensive disor-
der of pregnancy [51]. This is the current state-of-the-art
thinking. The renal biopsies of mild and severe disease
are similar, with severe disease having more pronounced
histologic changes. However, in both disease states, the
kidney almost always returns to normal. It is unclear why
there is such a large difference in clinical presentation
and recurrence between mild and severe disease.
DR. HARRINGTON: Is there any evidence that the fetus
itself might contribute to the toxins released that produce
preeclampsia, or is it the assumption that virtually all the
evil humors come from the placenta?
DR. LAFAYETTE: I would have to say there is no
great evidence that the fetus directly contributes. Some
observations suggest that when the fetus is unwell or
growing poorly, it produces signals that initiate or worsen
preeclampsia [52]. Analysis of the different fetus type
in terms of HLA type, gender, or developmental stage
has not revealed evidence implicating the fetus, per se.
It is more likely that the placental-uterine component
determines disease, as suggested by the fact that molar
pregnancies can cause preeclampsia in the absence of a
fetus [53].
DR. DRUZIN: In terms of fetal contribution to this dis-
ease, may we discuss the thrombophilias, both inherited
and acquired? Inherited thrombophilias such as Factor V
Leiden, prothrombin gene mutation, and hyperhomocys-
teinemia are risk factors for preeclampsia and placental
insufficiency. In our preliminary studies, we showed that,
in fact, mother/fetus pairs expressing the same gene dis-
order have a higher prevalence of severe disease [54].
That has not really held up in larger studies, but different
outcomes used in different studies have led to contro-
versy concerning the contribution of thrombophilias in
these patients. If mother and fetus both have long-chain
fatty acid deficiency, acute fatty liver of pregnancy is very
common. This disease presents in a very similar fashion to
HELLP syndrome and preeclampsia and can be difficult
to diagnose. There is therefore evidence of a fetal contri-
bution to this clinical entity. The mechanism is unclear,
but the placenta is a fetal organ attached to the pregnant
patient. We do not have a complete understanding of this
interface at the present time.
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